Surufatinib-induced renal thrombotic microangiopathy: first case report and review of literature

Angiogenesis inhibitors such as tyrosine kinase inhibitors (TKIs) are common therapeutics currently used to treat oncologic disease. Surufatinib is a novel, small-molecule multiple receptor TKI approved by the National Medical Products Administration (NMPA) for the treatment of progressive, advanced...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Wenjiao, Wang, Wei, Shi, Yuanping, Shen, Bo, Li, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2023
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611822/
https://www.ncbi.nlm.nih.gov/pubmed/37101053
http://dx.doi.org/10.1007/s00428-023-03545-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10611822/
https://www.ncbi.nlm.nih.gov/pubmed/37101053
http://dx.doi.org/10.1007/s00428-023-03545-2

Ejemplares similares